Welcome to our dedicated page for HEALTH LOGC INTERACTIVE news (Ticker: CHYPF), a resource for investors and traders seeking the latest updates and insights on HEALTH LOGC INTERACTIVE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HEALTH LOGC INTERACTIVE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HEALTH LOGC INTERACTIVE's position in the market.
Health Logic Interactive has signed a non-binding letter of intent to sell its subsidiary, My Health Logic, to Marizyme, Inc. The deal is expected to involve Marizyme issuing 4.6 million shares as consideration. The transaction requires due diligence and shareholder approval. Marizyme is advancing its DuraGraft technology, currently under FDA review. Following the sale, Health Logic intends to seek new assets and plans to reactivate its listing on the TSXV after meeting Tier 2 requirements. A conference call is scheduled for August 16, 2021, to discuss the transaction.
Health Logic Interactive Inc. (TSXV: CHIP.H; OTCPK: CHYPF) announced progress towards a Pre-Submission Meeting with the FDA for its MATLOC 1 diagnostic device, scheduled for September 2021. This meeting aims to obtain guidance on device classification, predicate devices, and necessary clinical data for FDA submission. The company will work with Reveles Clinical Service for regulatory strategy and clinical trial management. CEO David Barthel expressed optimism about this step, viewing it as crucial for de-risking the FDA application process and advancing towards approval.
Health Logic Interactive Inc. (TSXV: CHIP.H, OTCPK: CHYPF) announced updates on its MATLOC 1 digital diagnostic device, focusing on biomarkers for chronic kidney disease. Significant advancements include the completion of an optical measurement sub-system and testing of a fluid handling sub-system. The design of a urine sampling cartridge is underway, with user interaction studies expected to conclude by mid-July. The company aims for MATLOC 1 to integrate with lab-on-chip technology and plans to submit it for FDA review, supporting its mission for early CKD detection.
Health Logic Interactive (CHYPF) announced significant support for its chronic kidney disease (CKD) technology from Dr. Lesley A. Inker, Director at Tufts Medical Center. In her letter, she recognizes the potential of their lab-on-chip device for early CKD detection, emphasizing the importance of home-based GFR assessments. Dr. Rigatto, the Chief Medical Officer, highlighted the alarming statistic that over 1 in 7 U.S. adults have CKD and most are unaware. Health Logic aims to bridge the testing gap and improve patient outcomes through its innovative technology.
Health Logic Interactive announced positive preliminary proof-of-concept results for its urine creatinine chip prototype (uC-Chip beta). The tests confirmed clinically relevant detection capabilities. Concurrently, the Company aims to optimize the uC-Chip and is advancing its integrated urine albumin-to-creatinine ratio chip (uACR-Chip) prototype. This technology is anticipated to enhance point-of-care testing for chronic kidney disease. Health Logic is preparing for a pre-submission meeting with the FDA to further discuss the uACR-Chip's regulatory path.
Health Logic Interactive Inc. (TSXV: CHIP.H, OTCPK: CHYPF) has appointed nephrology experts Dr. Adeera Levin, Dr. Lesley Inker, and Dr. Susan Quaggin to its Scientific Advisory Board. This strategic move aims to enhance guidance as the company seeks FDA approval for its MATLOC digital diagnostic device and develops its product reimbursement strategy in the chronic kidney disease (CKD) sector. The inaugural SAB meeting focuses on point-of-care diagnostics and commercialization plans. Health Logic integrates handheld devices with smartphone technology to facilitate early detection of CKD.
Health Logic Interactive Inc. (TSXV: CHIP.H, OTCPK: CHYPF) announced the launch of a lab-on-chip innovation center through a five-year Professorship at a Canadian University. This initiative aims to enhance research in lab-on-chip technologies for disease diagnosis and therapeutic applications. The Company will contribute $50,000 annually to support this Professorship. Additionally, Health Logic granted 1,950,000 stock options to directors and consultants at an exercise price of $0.20, set to expire on May 31, 2024.
Health Logic Interactive Inc. (TSXV: CHIP.H, OTC: CHYPF) announced the receipt of a supportive letter from Dr. Chirag R. Parikh, Director of Nephrology at Johns Hopkins University, endorsing its lab-on-chip device for early detection of chronic kidney disease (CKD). Dr. Parikh highlighted the device's potential to enhance screening for CKD, addressing a critical need for accessible monitoring solutions. Additionally, Health Logic was featured in Stat News, further solidifying its position in the health tech space. The company's mission focuses on empowering patients with early detection and actionable management for CKD.
Health Logic Interactive Inc. (TSXV: CHIP.H, OTCPK: CHYPF) has issued its first letter to shareholders, highlighting the company's innovative digital diagnostic technology aimed at Chronic Kidney Disease (CKD). The CEO emphasized plans for quarterly updates and strategic milestones including a capital financing announcement, progress in product development, and pursuing FDA approval for its lab-on-chip technology. Health Logic aims to enhance patient care through smartphone integration, while building a robust leadership team. The company remains committed to increasing shareholder value and fostering transparency.
FAQ
What is the market cap of HEALTH LOGC INTERACTIVE (CHYPF)?
